PMID- 21337314
OWN - NLM
STAT- MEDLINE
DCOM- 20110907
LR  - 20191112
IS  - 1724-6008 (Electronic)
IS  - 0393-6155 (Linking)
VI  - 26
IP  - 1
DP  - 2011 Jan-Mar
TI  - Combined evaluation of matrix metalloproteinases and their inhibitors has better 
      clinical utility in oral cancer.
PG  - 27-36
AB  - BACKGROUND: Oral cancer is a major health hazard worldwide with increasing 
      incidence and mortality. Cervical lymph node metastasis is a major determinant of 
      outcome in oral cancer. The matrix metalloproteinase (MMP) system is critically 
      involved in invasion and metastasis. Assessment of MMPs and tissue inhibitors of 
      MMPs (TIMPs) in certain combinations might have better clinical efficacy given 
      their potential role in the metastatic process. AIM: Plasma concentrations of 
      MMP-2, MMP-9, TIMP-1 and TIMP-2 in 50 controls and 75 oral cancer patients 
      (nonmetastatic, n=54; metastatic, n=21) were evaluated to assess their 
      investigative value and role in predicting the behavior of this malignancy. 
      METHODS: The plasma concentrations of MMP-2, MMP-9, TIMP-1 and TIMP-2 were 
      quantified by ELISA. The best 2- and 3-marker combinations were calculated using 
      the statistical software mROC. The diagnostic values for all the biomolecules as 
      single markers and their combinations were estimated using the measures of 
      diagnostic accuracy, i.e. the area under the ROC curve and the sensitivity and 
      specificity at cutoff limits with the highest diagnostic accuracy and at the 95% 
      limits of sensitivity and specificity, respectively. RESULTS: MMP-9, TIMP-1 and 
      TIMP-2 were significantly elevated (p=0.000, p=0.013 and p=0.005, respectively) 
      in oral cancer patients. MMP-9 emerged as the best single statistically 
      significant marker in plasma for oral cancer detection. It showed an increase in 
      diagnostic performance when tested in combination with MMP-2 and TIMP-2. The 
      median plasma MMP-9 levels were elevated in both the metastatic and nonmetastatic 
      groups compared with controls (p<0.004 and p<0.007, respectively). CONCLUSION: 
      The results indicated that plasma MMP and TIMP levels in relevant combinations 
      may facilitate clinical decisionmaking for improved management of oral cancer 
      patients and may provide important data for selecting patients for treatment with 
      drugs that interfere with MMP and TIMP activities.
FAU - Singh, Ragini D
AU  - Singh RD
AD  - Biochemistry Research Division, The Gujarat Cancer & Research Institute, 
      Ahmedabad, Gujarat, India.
FAU - Nilayangode, Haridas
AU  - Nilayangode H
FAU - Patel, Jayendra B
AU  - Patel JB
FAU - Shah, Franky D
AU  - Shah FD
FAU - Shukla, Shilin N
AU  - Shukla SN
FAU - Shah, Pankaj M
AU  - Shah PM
FAU - Patel, Prabhudas S
AU  - Patel PS
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Int J Biol Markers
JT  - The International journal of biological markers
JID - 8712411
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (Tissue Inhibitor of Metalloproteinases)
RN  - EC 3.4.24.- (Matrix Metalloproteinases)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Biomarkers, Tumor
MH  - Enzyme-Linked Immunosorbent Assay
MH  - Female
MH  - Humans
MH  - Lymphatic Metastasis/*diagnosis
MH  - Male
MH  - Matrix Metalloproteinases/*blood
MH  - Middle Aged
MH  - Mouth Neoplasms/blood/*diagnosis/pathology
MH  - Neoplasm Invasiveness
MH  - Prognosis
MH  - Tissue Inhibitor of Metalloproteinases/*blood
EDAT- 2011/02/22 06:00
MHDA- 2011/09/08 06:00
CRDT- 2011/02/22 06:00
PHST- 2011/01/10 00:00 [accepted]
PHST- 2011/02/22 06:00 [entrez]
PHST- 2011/02/22 06:00 [pubmed]
PHST- 2011/09/08 06:00 [medline]
AID - A5609D6A-8CA5-462E-B92F-36DB050F62A0 [pii]
AID - 10.5301/jbm.2011.6359 [doi]
PST - ppublish
SO  - Int J Biol Markers. 2011 Jan-Mar;26(1):27-36. doi: 10.5301/jbm.2011.6359.